{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:21:22Z","timestamp":1790230882344,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.bcp.2010.05.003","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T06:10:27Z","timestamp":1274076627000},"page":"592-601","source":"Crossref","is-referenced-by-count":58,"title":["Targeted therapy of thyroid cancer"],"prefix":"10.1016","volume":"80","author":[{"given":"Steven I.","family":"Sherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2010.05.003_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2010.05.003_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<34::AID-SSU7>3.0.CO;2-2","article-title":"Management of the patient with progressive radioiodine non-responsive disease","volume":"16","author":"Haugen","year":"1999","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib3","series-title":"Practical management of thyroid cancer: a multidisciplinary approach","first-page":"429","article-title":"Clinical trials for thyroid carcinoma: past, present, and future","author":"Sherman","year":"2006"},{"key":"10.1016\/j.bcp.2010.05.003_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2010.05.003_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy","volume":"183","author":"Fagin","year":"2004","journal-title":"J Endocrinol"},{"key":"10.1016\/j.bcp.2010.05.003_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2010.05.003_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.003_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem.86.2.7226","article-title":"Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/msy.2001.112592","article-title":"Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer","volume":"129","author":"Lennard","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.bcp.2010.05.003_bib11","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1210\/jc.2005-2836","article-title":"Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer","volume":"91","author":"Jo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib12","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.17.3682","article-title":"Refractory thyroid cancer: a paradigm shift in treatment is not far off","volume":"26","author":"Pfister","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","article-title":"Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets","volume":"21","author":"Knauf","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.bcp.2010.05.003_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2796.2009.02112.x","article-title":"Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma","volume":"266","author":"Santarpia","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.bcp.2010.05.003_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncponc1037","article-title":"Drug Insight: gastrointestinal stromal tumors (GIST)\u2014the solid tumor model for cancer-specific treatment","volume":"5","author":"Sleijfer","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1541-7786.MCR-07-2001","article-title":"BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells","volume":"6","author":"Sala","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib17","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/jco.2009.27.15_suppl.9000","article-title":"Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer","volume":"27","author":"Flaherty","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib18","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells","author":"Salerno","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib19","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors","volume":"27","author":"Schwartz","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib20","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib21","first-page":"920","article-title":"Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts","volume":"16","author":"Coxon","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib22","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2010.05.003_bib24","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.bcp.2010.05.003_bib26","unstructured":"Sherman SI, Schlumberger MJ, Elisei R, Wirth L, Bastholt L, Droz J-P, et al. Exacerbation of postsurgical hypothyroidism during treatment of thyroid carcinoma with motesanib diphosphate (AMG 706). 89th annual meeting of the Endocrine Society. Toronto, ON; 2007."},{"key":"10.1016\/j.bcp.2010.05.003_bib27","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2010.05.003_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2010.05.003_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib31","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib32","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/jco.2006.24.18_suppl.5534","article-title":"Significant clinical and biologic activity of RAF\/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study","volume":"24","author":"Kloos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib33","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib34","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/jco.2009.27.15_suppl.6002","article-title":"Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients","volume":"27","author":"Brose","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EJE-09-0702","article-title":"Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma","volume":"161","author":"Hoftijzer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bcp.2010.05.003_bib36","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1200\/jco.2009.27.15_suppl.6060","article-title":"Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): the M. D. Anderson Cancer Center (MDACC) experience","volume":"27","author":"Cabanillas","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib37","unstructured":"Cabanillas ME, Kurzrock R, Bidyasar S, Wheeler J, Fu S, Naing A, et al. Phase I trial of a combination of sorafenib and tipifarnib: update on the experience in advanced thyroid malignancies (NCI Protocol#7156). World congress on thyroid cancer. Toronto; 2009."},{"key":"10.1016\/j.bcp.2010.05.003_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/CCO.0b013e32801173ea","article-title":"Medullary thyroid cancer: therapeutic targets and molecular markers","volume":"19","author":"Ball","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib39","doi-asserted-by":"crossref","first-page":"14065","DOI":"10.1200\/jco.2007.25.18_suppl.14065","article-title":"Effect of sorafenib in symptomatic metastatic medullary thyroid cancer","volume":"25","author":"Kober","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib40","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib41","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-05-2378","article-title":"BRAF is a therapeutic target in aggressive thyroid carcinoma","volume":"12","author":"Salvatore","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.6058","article-title":"Phase II trial of sorafenib (BAY 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)","volume":"27","author":"Nagaiah","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib43","unstructured":"Sherman SI. NCCN practice guidelines for thyroid cancer, version 2009a.; 2009."},{"key":"10.1016\/j.bcp.2010.05.003_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.2008.0429","article-title":"The successful use of sorafenib to treat pediatric papillary thyroid carcinoma","volume":"19","author":"Waguespack","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib45","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2010.05.003_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0b013e3282fc6cf7","article-title":"Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma","volume":"19","author":"Dawson","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2010.05.003_bib48","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/jco.2008.26.15_suppl.6025","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib49","doi-asserted-by":"crossref","unstructured":"Ravaud A, de la Fouchardi\u00e8re C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial; 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.6058"},{"key":"10.1016\/j.bcp.2010.05.003_bib50","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1200\/jco.2009.27.15_suppl.6056","article-title":"Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC)","volume":"27","author":"Carr","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.16.2.239","article-title":"Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis","volume":"16","author":"Herbst","year":"2007","journal-title":"Expert Opin Investigational Drugs"},{"key":"10.1016\/j.bcp.2010.05.003_bib52","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib53","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib54","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2010.05.003_bib55","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib57","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib58","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1200\/jco.2008.26.15_suppl.6024","article-title":"A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"26","author":"Haddad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.10014","article-title":"Phase I\/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma","volume":"27","author":"Fox","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib60","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1210\/jc.2005-2472","article-title":"Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro","volume":"91","author":"Mitsiades","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2010.05.003_bib62","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib63","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib64","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","article-title":"Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies","volume":"64","author":"Bocci","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib65","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1200\/jco.2009.27.15_suppl.3521","article-title":"Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers","volume":"27","author":"Bible","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.surg.2005.10.019","article-title":"Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations","volume":"139","author":"de Groot","year":"2006","journal-title":"Surgery"},{"key":"10.1016\/j.bcp.2010.05.003_bib67","first-page":"3601","article-title":"RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571","volume":"23","author":"Skinner","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib68","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-06-0695","article-title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma","volume":"157","author":"Frank-Raue","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bcp.2010.05.003_bib70","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase-II trial of imatinib therapy for metastatic medullary thyroid carcinoma","volume":"92","author":"de Groot","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib71","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.1200\/jco.2006.24.18_suppl.13048","article-title":"Phase I\/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC)","volume":"24","author":"Hoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib72","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1200\/jco.2009.27.15_suppl.6057","article-title":"Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC)","volume":"27","author":"Ha","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib73","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib74","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England J Med"},{"key":"10.1016\/j.bcp.2010.05.003_bib75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"Pennell","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib76","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-006-0286-6","article-title":"A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors","volume":"59","author":"Fury","year":"2007","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"10.1016\/j.bcp.2010.05.003_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2007.05.012","article-title":"Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification","volume":"39","author":"Elliott","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bcp.2010.05.003_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1078155208101212","article-title":"Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib","volume":"15","author":"Hogan","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bcp.2010.05.003_bib79","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/13543776.17.9.1035","article-title":"Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications","volume":"17","author":"Cui","year":"2007","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bcp.2010.05.003_bib80","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1210\/en.2003-1762","article-title":"Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels","volume":"145","author":"Mineo","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2010.05.003_bib81","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.pas.0000156103.37756.e2","article-title":"MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma","volume":"29","author":"Wasenius","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bcp.2010.05.003_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/EP:11:1:19","article-title":"Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid","volume":"11","author":"Papotti","year":"2000","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.bcp.2010.05.003_bib83","unstructured":"Kurzrock R, Sherman S, Pfister D, Cohen RB, Ball D, Hong D, et al. Preliminary results of a phase I study of XL184, a MET, VEGFR2 and RET kinase inhibitor (TKI), administered orally to patients with medullary thyroid cancer (MTC). 34th annual meeting of the European Thyroid Association. Lisbon; 2009."},{"key":"10.1016\/j.bcp.2010.05.003_bib84","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2010.05.003_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2000.10.587","article-title":"Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion","volume":"10","author":"Ain","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/thy.2006.0289","article-title":"Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas","volume":"17","author":"Ain","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib87","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/jco.2008.26.15_suppl.6027","article-title":"Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine unresponsive thyroid carcinomas: preliminary results","volume":"26","author":"Ain","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11912-005-0033-x","article-title":"Novel vascular targeting\/disrupting agents: combretastatin A4 phosphate and related compounds","volume":"7","author":"Cooney","year":"2005","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bcp.2010.05.003_bib89","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1210\/jc.2007-0027","article-title":"Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model","volume":"92","author":"Yeung","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib90","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/105072502321085153","article-title":"Combretastatin a4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors","volume":"12","author":"Dziba","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib91","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2008-1102","article-title":"DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification","author":"Schweppe","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/thy.2008.0321","article-title":"A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome","volume":"19","author":"Mooney","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib93","unstructured":"ClinicalTrials.gov. National Institutes of Health."},{"key":"10.1016\/j.bcp.2010.05.003_bib94","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1210\/jc.2005-2498","article-title":"Phase II study of celecoxib in metastatic differentiated thyroid carcinoma","volume":"91","author":"Mrozek","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ecl.2007.12.002","article-title":"Epigenetic dysregulation in thyroid neoplasia","volume":"37","author":"Kondo","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bcp.2010.05.003_bib96","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1568008043339811","article-title":"Redifferentiation therapy in advanced thyroid cancer","volume":"4","author":"Haugen","year":"2004","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.bcp.2010.05.003_bib97","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","article-title":"Histone deacetylase inhibitors as anti-neoplastic agents","volume":"280","author":"Batty","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bcp.2010.05.003_bib98","first-page":"3430","article-title":"Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)\/I(\u2212) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells","volume":"86","author":"Kitazono","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib99","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1210\/en.2003-1258","article-title":"Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium\/iodide symporter thyroperoxidase and thyroglobulin","volume":"145","author":"Furuya","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2010.05.003_bib100","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1200\/jco.2008.26.15_suppl.3571","article-title":"Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers","volume":"28","author":"Piekarz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib101","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1200\/jco.2009.27.15_suppl.6059","article-title":"Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma","volume":"27","author":"Sherman","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.bcp.2010.05.003_bib102","first-page":"928","article-title":"Phase II study of oral histone deacetylase inhibitor SAHA in patients with metastatic thyroid cancer","volume":"14","author":"Ringel","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.bcp.2010.05.003_bib103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies","volume":"16","author":"Smallridge","year":"2009","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib104","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1677\/ERC-07-0096","article-title":"Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines","volume":"14","author":"Catalano","year":"2007","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib105","first-page":"515","article-title":"Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib","volume":"21","author":"Catalano","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bcp.2010.05.003_bib106","first-page":"1353","article-title":"Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin","volume":"34","author":"Kim","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib107","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","article-title":"Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers","volume":"14","author":"Braiteh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib108","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1210\/en.2006-0927","article-title":"Gene methylation in thyroid tumorigenesis","volume":"148","author":"Xing","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2010.05.003_bib109","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/cbr.2006.319.A","article-title":"The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake","volume":"22","author":"Tuncel","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.bcp.2010.05.003_bib110","first-page":"2449","article-title":"Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+\/I-symporter gene methylation status","volume":"84","author":"Venkataraman","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib111","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00000478-199906000-00007","article-title":"Downregulation of p27KIP1 and Ki67\/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories","volume":"23","author":"Tallini","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bcp.2010.05.003_bib112","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.otohns.2007.07.030","article-title":"Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)","volume":"137","author":"Provenzano","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.bcp.2010.05.003_bib113","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/jc.2006-2106","article-title":"Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium\/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor","volume":"92","author":"Li","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib114","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1210\/jcem-71-3-755","article-title":"Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro","volume":"71","author":"Van Herle","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1530\/eje.0.1480395","article-title":"Retinoic acid for redifferentiation of thyroid cancer\u2014does it hold its promise?","volume":"148","author":"Gruning","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bcp.2010.05.003_bib116","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/eje.1.02123","article-title":"Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma","volume":"154","author":"Liu","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bcp.2010.05.003_bib117","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.surg.2006.07.038","article-title":"A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer","volume":"140","author":"Kebebew","year":"2006","journal-title":"Surgery"},{"key":"10.1016\/j.bcp.2010.05.003_bib118","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib119","first-page":"983","article-title":"Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma","volume":"85","author":"Vitale","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10637-007-9091-2","article-title":"A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer","volume":"26","author":"Argiris","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bcp.2010.05.003_bib121","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","article-title":"Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination","volume":"86","author":"Schott","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2010.05.003_bib122","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1158\/1078-0432.CCR-03-0698","article-title":"Dendritic cell vaccination in medullary thyroid carcinoma","volume":"10","author":"Stift","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib123","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2007-1022565","article-title":"Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma","volume":"40","author":"Papewalis","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.bcp.2010.05.003_bib124","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3892\/or_00000391","article-title":"Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma","volume":"21","author":"Bachleitner-Hofmann","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bcp.2010.05.003_bib125","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","article-title":"Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group","volume":"24","author":"Chatal","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.05.003_bib126","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2010.05.003_bib127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2009.02.007","article-title":"Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited","volume":"15","author":"Loges","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210003424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210003424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T21:15:54Z","timestamp":1635369354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295210003424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0006295210003424"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2010.05.003","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}